Shaanxi Kanghui Pharm Co Ltd Asset Resilience Ratio
Shaanxi Kanghui Pharm Co Ltd asset resilience ratio. Shaanxi Kanghui Pharm Co Ltd (603139) has an Asset Resilience Ratio of 0.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603139 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shaanxi Kanghui Pharm Co Ltd (2019–2025)
Asset resilience ratio of Shaanxi Kanghui Pharm Co Ltd from 2019 to 2025. This chart shows how Shaanxi Kanghui Pharm Co Ltd's Asset Resilience Ratio has changed over time. Read 603139 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shaanxi Kanghui Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shaanxi Kanghui Pharm Co Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥252.20K | 0.01% |
| Total Liquid Assets | CN¥252.20K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Shaanxi Kanghui Pharm Co Ltd maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shaanxi Kanghui Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shaanxi Kanghui Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Shaanxi Kanghui Pharm Co Ltd Asset Resilience Ratio by Year (2019–2025)
Shaanxi Kanghui Pharm Co Ltd asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Shaanxi Kanghui Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | CN¥252.20K ≈ $36.90K |
CN¥1.81 Billion ≈ $265.51 Million |
-0.01pp |
| 2024-12-31 | 0.02% | CN¥359.18K ≈ $52.56K |
CN¥1.89 Billion ≈ $276.25 Million |
-0.13pp |
| 2023-12-31 | 0.15% | CN¥3.02 Million ≈ $441.85K |
CN¥2.05 Billion ≈ $300.23 Million |
-0.10pp |
| 2022-12-31 | 0.25% | CN¥4.50 Million ≈ $658.73K |
CN¥1.82 Billion ≈ $266.57 Million |
-6.18pp |
| 2021-12-31 | 6.42% | CN¥119.47 Million ≈ $17.48 Million |
CN¥1.86 Billion ≈ $272.21 Million |
+2.19pp |
| 2020-12-31 | 4.23% | CN¥55.47 Million ≈ $8.12 Million |
CN¥1.31 Billion ≈ $191.87 Million |
-12.75pp |
| 2019-12-31 | 16.98% | CN¥192.00 Million ≈ $28.10 Million |
CN¥1.13 Billion ≈ $165.45 Million |
-- |
About Shaanxi Kanghui Pharm Co Ltd
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biolo… Read more